INTRODUCTION: Beyond documentation of high prevalence rates, research has not examined the qualities and characteristics of musculoskeletal symptoms in cancer survivors, possibly because measures have not been validated specifically for the assessment of these symptoms in survivors. We report here on a new measure of muscle and joint symptoms for survivors of hematologic malignancies and hematopoietic cell transplantation (HCT). METHODS: In a cross-sectional design, 130 adults, 5-20 years after HCT, completed patient-reported outcomes. Assessment included musculoskeletal symptoms on the Muscle and Joint Measure (MJM), as well as health-related quality of life and treatments. RESULTS: Principal components analysis using promax rotation revealed four subscales for the MJM with item factor loadings above 0.50: muscle aches or stiffness (myalgias), joint pain, stiffness or swelling (arthralgias), muscle cramps, and muscle weakness. Variance explained by the total score was 77%. Internal consistency reliabilities of the subscales and total score ranged from 0.86 to 0.93. Validity was confirmed by correlations with the Short Form-36 bodily pain, physical function and vitality subscales, the Fatigue Symptom Inventory, and the Symptom Checklist-90-R depression (all P < .001). CONCLUSIONS: Musculoskeletal symptoms in survivors who received HCT can be measured reliably and validly with the MJM. The measure requires testing to establish its psychometric properties with other diagnostic and treatment groups. IMPLICATIONS FOR CANCER SURVIVORS: The MJM has potential research and clinical value for addressing the musculoskeletal symptoms of survivors. The measure may assist with examining the mechanisms as well as treatments for these symptoms, which are among the most prevalent in long-term cancer survivors.
INTRODUCTION: Beyond documentation of high prevalence rates, research has not examined the qualities and characteristics of musculoskeletal symptoms in cancer survivors, possibly because measures have not been validated specifically for the assessment of these symptoms in survivors. We report here on a new measure of muscle and joint symptoms for survivors of hematologic malignancies and hematopoietic cell transplantation (HCT). METHODS: In a cross-sectional design, 130 adults, 5-20 years after HCT, completed patient-reported outcomes. Assessment included musculoskeletal symptoms on the Muscle and Joint Measure (MJM), as well as health-related quality of life and treatments. RESULTS: Principal components analysis using promax rotation revealed four subscales for the MJM with item factor loadings above 0.50: muscle aches or stiffness (myalgias), joint pain, stiffness or swelling (arthralgias), muscle cramps, and muscle weakness. Variance explained by the total score was 77%. Internal consistency reliabilities of the subscales and total score ranged from 0.86 to 0.93. Validity was confirmed by correlations with the Short Form-36 bodily pain, physical function and vitality subscales, the Fatigue Symptom Inventory, and the Symptom Checklist-90-R depression (all P < .001). CONCLUSIONS:Musculoskeletal symptoms in survivors who received HCT can be measured reliably and validly with the MJM. The measure requires testing to establish its psychometric properties with other diagnostic and treatment groups. IMPLICATIONS FOR CANCER SURVIVORS: The MJM has potential research and clinical value for addressing the musculoskeletal symptoms of survivors. The measure may assist with examining the mechanisms as well as treatments for these symptoms, which are among the most prevalent in long-term cancer survivors.
Authors: Charles S Cleeland; Gary J Bennett; Robert Dantzer; Patrick M Dougherty; Adrian J Dunn; Christina A Meyers; Andrew H Miller; Richard Payne; James M Reuben; Xin Shelley Wang; Bang-Ning Lee Journal: Cancer Date: 2003-06-01 Impact factor: 6.860
Authors: Karen L Syrjala; Shelby L Langer; Janet R Abrams; Barry Storer; Jean E Sanders; Mary E D Flowers; Paul J Martin Journal: JAMA Date: 2004-05-19 Impact factor: 56.272
Authors: Emily Jo Rajotte; Jean C Yi; K Scott Baker; Lindsey Gregerson; Andréa Leiserowitz; Karen L Syrjala Journal: J Cancer Surviv Date: 2012-01-13 Impact factor: 4.442
Authors: Margaret F Bevans; Sandra A Mitchell; John A Barrett; Michael R Bishop; Richard Childs; Daniel Fowler; Michael Krumlauf; Patricia Prince; Nonniekaye Shelburne; Leslie Wehrlen; Li Yang Journal: Biol Blood Marrow Transplant Date: 2013-12-17 Impact factor: 5.742
Authors: Paul A Glare; Pamela S Davies; Esmé Finlay; Amitabh Gulati; Dawn Lemanne; Natalie Moryl; Kevin C Oeffinger; Judith A Paice; Michael D Stubblefield; Karen L Syrjala Journal: J Clin Oncol Date: 2014-05-05 Impact factor: 44.544
Authors: Paul A Carpenter; Carrie L Kitko; Sharon Elad; Mary E D Flowers; Juan C Gea-Banacloche; Jörg P Halter; Flora Hoodin; Laura Johnston; Anita Lawitschka; George B McDonald; Anthony W Opipari; Bipin N Savani; Kirk R Schultz; Sean R Smith; Karen L Syrjala; Nathaniel Treister; Georgia B Vogelsang; Kirsten M Williams; Steven Z Pavletic; Paul J Martin; Stephanie J Lee; Daniel R Couriel Journal: Biol Blood Marrow Transplant Date: 2015-03-31 Impact factor: 5.742
Authors: Karen L Syrjala; Allison C Stover; Jean C Yi; Samantha B Artherholt; Eleni M Romano; Gary Schoch; Susan Stewart; Mary E D Flowers Journal: J Cancer Surviv Date: 2011-05-05 Impact factor: 4.442
Authors: Margaret Bevans; Areej El-Jawahri; D Kathryn Tierney; Lori Wiener; William A Wood; Flora Hoodin; Erin E Kent; Paul B Jacobsen; Stephanie J Lee; Matthew M Hsieh; Ellen M Denzen; Karen L Syrjala Journal: Biol Blood Marrow Transplant Date: 2016-09-19 Impact factor: 5.742
Authors: A M J Braamse; B van Meijel; O Visser; P C Huijgens; A T F Beekman; J Dekker Journal: Bone Marrow Transplant Date: 2013-10-07 Impact factor: 5.483
Authors: Bonnie J Furzer; Kemi E Wright; Anna S Petterson; Karen E Wallman; Timothy R Ackland; David J L Joske Journal: BMC Complement Altern Med Date: 2013-07-11 Impact factor: 3.659
Authors: Mario E Lacouture; Brigitte Dréno; Paolo Antonio Ascierto; Reinhard Dummer; Nicole Basset-Seguin; Kate Fife; Scott Ernst; Lisa Licitra; Rogerio I Neves; Ketty Peris; Susana Puig; Jonas Sokolof; Aleksandar Sekulic; Axel Hauschild; Rainer Kunstfeld Journal: Oncologist Date: 2016-08-10